Working… Menu
Trial record 47 of 2874 for:    Pancreatic Cancer AND pancreas

A Trial of Chemo & Radiation Therapy for Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00424827
Recruitment Status : Completed
First Posted : January 22, 2007
Results First Posted : June 1, 2017
Last Update Posted : June 1, 2017
Information provided by (Responsible Party):
University of Massachusetts, Worcester

Brief Summary:
This is an open-label, non-randomized, combination study of cetuximab, gemcitabine, 5-FU, and external beam radiotherapy in patients with locally advanced, non-metastatic pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Gemcitabine/Fluorouracil with External Beam Radiation Phase 2

Detailed Description:

During cycle I (chemoradiation), gemcitabine (200 mg/m2) and cetuximab 400mg/m2 initial dose followed by 250mg/m2 IV weekly will be given with continuous infusion 5-FU (200 mg/m2/day) delivered 5 of every 7 days and concurrent external beam radiation therapy. Cetuximab, gemcitabine and 5-FU will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy. All patients will have a central venous access device placed to facilitate chemotherapy administration.

During cycles 2 through 5 (chemotherapy), gemcitabine will be administered at a dose of 1000 mg/m2 over 30 minutes followed by cetuximab at a dose of 250mg/m2 over 30 minutes weekly for 3 weeks followed by one-week rest for four cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Study Start Date : June 2006
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Experimental: Gemcitabine/Fluorouracil with External Beam Radiation
This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
Drug: Gemcitabine/Fluorouracil with External Beam Radiation
This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
Other Name: EGFR Expression; Cetuximab & Radiosensitization of Cetuximab

Primary Outcome Measures :
  1. Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy. [ Time Frame: 1-year ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Secondary Outcome Measures :
  1. Biomarker Response to Chemoradiation Therapy [ Time Frame: 1-year ]
    20% decrease in biomarker (CA19-9) from baseline

  2. Resection Rate [ Time Frame: 1-Year ]
  3. Overall Survival [ Time Frame: Up to 2 years ]
  4. Toxicity Associated With This Regimen. [ Time Frame: 1-Year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological confirmation of pancreatic adenocarcinoma is required.
  • Only patients with unresectable, non-metastatic tumors are eligible.
  • Documentation of disease extent by endoscopic ultrasound and either laparotomy or laparoscopy must be performed within 42 days of registration.
  • All patients will also be assessed by chest x-ray and abdominal-pelvic CT scan.
  • Confirmation of palliative surgical bypass at the time of laparotomy or whether a biliary stent was placed will be requested.
  • Disease must be locoregional and not amenable to surgery based on one or more of the following criteria:

    • size of pancreatic tumor > 5 cm.
    • lymph nodes (bulky, > 2 cm, but within a radiation port)
    • vascular involvement or impingement of major vessels (superior mesenteric artery, superior mesenteric vein, portal vein, hepatic artery).
    • invasion into the adjacent structures.
  • Patients with either measurable or evaluable disease are eligible.
  • Patients with evidence of peritoneal seeding by malignancy are not eligible for the study.
  • Patients with other evidence of metastatic disease are not eligible.
  • Patients with concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.
  • Patients with any other malignancy within 5 years of study entry, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.
  • Patients may not have had prior therapy for carcinoma of the pancreas, nor prior abdominal radiation therapy.
  • Age > 18 years.
  • CTC performance status < 2.
  • No myocardial infarction in the past six months.
  • No major surgery in the past two weeks.
  • No uncontrolled serious medical or psychiatric illness.
  • Required Initial Laboratory Data:

    • Total bilirubin < 2.0 mg/dl
    • AST < 3x upper limits of normal.
    • Serum creatinine < 2.0 mg/dl
    • WBC > 3,000/mm3 (ANC>1500/mm3)
    • Platelets > 100,000 mm3
    • CA 19-9
  • Required Diagnostic procedures:

    • Chest X-ray
    • Abdominal pelvic CT scan
    • EUS
    • Staging laparoscopy or staging laparotomy

Exclusion Criteria:

Enrollment in this trial will be limited to patients for whom protocol therapy is safe and appropriate. Physicians should consider the risks and benefits of therapy together with all relevant medical and other considerations in deciding whether this protocol is appropriate for a particular patient. Specific considerations include:

  • Psychiatric illness which would prevent the patient from giving informed consent.
  • Serious medical illness such as uncontrolled infection, severe cardiovascular disease including recent (< 6 months) myocardial infarction or uncontrolled congestive heart failure, or other serious illness which would limit anticipated survival to < 12 weeks.
  • Protocol treatment would pose significant risk to an unborn child. Pregnant women should not be enrolled, and women of child-bearing age should be strongly encouraged to practice effective birth control during and for three months after the trial.
  • Inability to swallow medication. Patients should have adequate, unassisted oral intake.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00424827

Sponsors and Collaborators
University of Massachusetts, Worcester
Layout table for investigator information
Principal Investigator: Venu Bathini, MD University of Massachusetts, Worcester

Layout table for additonal information
Responsible Party: University of Massachusetts, Worcester Identifier: NCT00424827     History of Changes
Other Study ID Numbers: UM200602
First Posted: January 22, 2007    Key Record Dates
Results First Posted: June 1, 2017
Last Update Posted: June 1, 2017
Last Verified: May 2017
Keywords provided by University of Massachusetts, Worcester:
pancreatic cancer, gemcitabine, 5-FU, cetuximab, radiation
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological